Apolipoprotein E2
Lexeo Therapeutics Unveils Promising Interim Data for LX1001 Gene Therapy in APOE4-Associated Alzheimer’s Disease
Lexeo Therapeutics, LX1001, Gene Therapy, Alzheimer’s Disease, APOE4, APOE2, Clinical Trial, Phase 1/2
Actionable Insights Powered by AI
Lexeo Therapeutics, LX1001, Gene Therapy, Alzheimer’s Disease, APOE4, APOE2, Clinical Trial, Phase 1/2